Browse Articles
Discover research articles across all indexed journals
A controllable doping method for Ga2O3 film construction and optimized density for high-performance photodetectors
Gallium oxide (Ga2O3), a wide bandgap semiconductor, has been extensively studied for its potential applications in deep ultraviolet photodetectors and next-generation power electronic devices. To enhance the optoelectronic properties of Ga2O3 films, a controllable doping strategy is proposed in this work. Using a sol-gel method, Ga2O3 films doped with magnesium (Mg) are prepared, with the Mg concentration adjustable through the precursor solution. The results indicate that the bandgap of Ga2O3 increases with higher doping levels, while the electrical conductivity decreases proportionally. To evaluate their optoelectronic characteristics, a series of photodetectors with Mg-doped Ga2O3 active layers are fabricated. Under a 254 nm incident light, the device with an optimal doping concentration of 4.2% demonstrates the best performance, achieving the highest responsivity (R) of 1.97 A/W and a photo-dark current ratio of 2.6 × 103. Furthermore, density functional theory calculations are employed to provide a detailed analysis of the fundamental mechanisms behind the enhanced optoelectronic properties. This approach to controllable and optimized doping in Ga2O3 films shows promise for future applications in semiconductor devices.
Prevalence and determinants of poor glycemic control among diabetic chronic kidney disease patients on maintenance hemodialysis in Tanzania
Background Poor glycemic control in diabetic chronic kidney disease (CKD) patients on maintenance hemodialysis is of great challenge, resulting in increased risk of morbidity and mortality. This study aimed to determine the prevalence and determinants of poor glycemic control among diabetic CKD patients on maintenance hemodialysis. Methodology A cross-sectional study was conducted in 12 dialysis centers located in four regions of Tanzania from March to June 2023. The study population was diabetic CKD patients above 18 years on maintenance hemodialysis for three months or more. A consecutive sampling technique was used for patient recruitment, and a semi-structured questionnaire was used to collect data. The primary outcome was poor glycemic control were considered when glycated hemoglobin (HbA1c) levels were < 6% or > 8%. Statistical Package for Social Sciences (SPSS) version 23 was used for data analysis. Univariate and multivariable regression models were used to evaluate the determinants of poor glycemic control. A p-value < 0.05 was considered statistically significant. Results Out of 233 enrolled patients, the overall prevalence of poor glycemic control was 55.4%, whereby 27.0% had HbA1c < 6% and 28.33% had HbA1c > 8%. A high risk of HbA1c > 8% was observed among patients who were on antidiabetic medication (2.16 (95% CI: 1.06–4.41) p = 0.035) and those attending dialysis sessions less than 3 times a week (1.59 (95% CI: 1.02–2.48) p = 0.040). The lower risk of HbA1c < 6% was observed in patients dialyzed using glucose-containing dialysates than those dialyzed with glucose-free dialysate (0.57 (95% CI 0.36–0.87) p = 0.020). Conclusion The high prevalence of poor glycemic control among diabetic CKD patients, as revealed by this study, has significant implications. Patients on antidiabetic medication and those with less than three dialysis sessions per week are at a high risk of HbA1c > 8%. Conversely, patients dialyzed using glucose-free dialysates are at a high risk of HbA1c < 6%. Glycemic control in diabetic chronic kidney disease (CKD) patients is a great challenge due to altered glucose homeostasis, gluconeogenesis, tubular glucose reabsorption and inaccuracy of glycemic regulation metrics [1]. Furthermore, changed renal pharmacokinetics of antihyperglycemic agents (AHA), uremic milieu, and dialysis therapy also contribute to this challenge [2]. Based on the severe risk of hyperglycemia and hypoglycemia in patients with diabetic end-stage renal disease (ESRD), glycemic control is of paramount importance.
Dynamic interplay of cNHEJ and MMEJ pathways of DNA double-strand break repair during embryonic development in zebrafish
Abstract Double strand breaks (DSBs) are the most deleterious DNA lesions as they frequently result in mutations when repaired by canonical non homologous end-joining (cNHEJ) and microhomology-mediated end-joining (MMEJ). Here, we investigated the relative importance of cNHEJ and MMEJ pathways during zebrafish embryonic development. We have analyzed the expression of cNHEJ and MMEJ related genes and found that it was dynamic during development and often become increased in specific tissues. We showed that inactivation of nuclear DNA ligase 3 (nLig3) or DNA polymerase theta (Polθ), two key MMEJ factors, did not affect zebrafish development but sensitized embryos to ionizing radiations and that deficiency of Polθ, but not nLig3, profoundly alters the mutation spectrum induced during repair of Cas9-mediated DSBs. By contrast, inactivation of DNA ligase 4, required for cNHEJ, did not seem to sensitize embryos to ionizing radiations nor to affect repair of Cas9-mediated DSBs but resulted in important larval growth defects. Our study underscores the dynamic and context-dependent roles of cNHEJ and MMEJ pathways during zebrafish development, highlighting their differential requirements across developmental stages and in response to genotoxic stress.
Novel urine-enriched RNA panel (EPCAM, TTC3, H4C5) to detect prostate cancer and differentiate it from benign prostatic disease.
31 Background: Prostate Cancer (PCa) is one of the leading causes of cancer deaths among men worldwide. Although the Prostate-Specific Antigen (PSA) test is widely used for screening, several advisory groups recommend against PSA because of its non-specific and suboptimal performance. Hence, there is an urgent unmet need for novel and more accurate biomarker panels for PCa detection. Methods: To develop an alternate assay, we collected voided urine (50 ml) from 236 pre- and 198 matched post-prostatectomy men with PCa, 76 benign prostatic hyperplasia (BPH), 21 prostatitis and 107 normal healthy men between the years 40-80. We isolated RNA from exfoliated cells and debris shed into urine, subjected to deep-sequencing of 50 selected genes (adj P value < 0.05 and log FC > 2), and performed advanced machine-learning approaches to discover potential biomarkers in men with PCa. Results: From 50 RNAs initially tested in 20 pooled urine samples, 3 RNAs (EPCAM, TTC3, H4C5) were identified to detect men with PCa robustly (with higher specificity and sensitivity) and distinguished them between pre- and post-prostatectomy in PCa patients. The biomarkers, in combination, outperformed a known urinary RNA marker, PCA3 (area under the curve, 0.96, Figure 1 left). Immunohistochemistry and qPCR analysis in prostate FFPE tissues further confirmed that the origin of these three biomarkers is prostate-specific. In addition, the biomarker panel could separate PCa from benign prostatic disease (area under the curve, 0.89), where both diseases show a higher elevation of PSA. TTC3 and EpCAM gene silencing in PCa cells showed a tumor suppression in vitro and in vivo , suggesting its relevance to PCa development. Conclusions: The urine-based RNA biomarker panel (EPCAM, TTC3, H4C5) is a promising noninvasive diagnostic tool to separate PCa from BPH/prostatitis and healthy individuals; further prospective validation is warranted.
Real-world prevalence and outcomes of androgen receptor ligand-binding domain mutations in prostate cancer.
93 Background: Anti-hormonal therapies targeting the androgen receptor (AR) pathway are the standard of care treatment for patients with prostate cancer (PC). However, patients can develop resistance to androgen receptor pathway inhibitors (ARPI), and one mechanism is due to AR ligand-binding domain mutations (AR LBDm). While evidence suggests AR LBDm may play a key role in disease progression, limited data on AR LBDm is available across PC clinical states. This study used large real-world data to assess mutations within 12 AR LBD genes reported in the literature supporting a potential resistance mechanism to ARPI and their association with patient survival. Methods: The Guardant INFORM de-identified real-world clinical-genomic database was utilized, which links comprehensive circulating tumor DNA (ctDNA) results (using the next-generation sequencing Guardant360 assay [G360]) to claims data. The study included U.S. PC patients who had G360 testing between June 2014 and June 2023. A 6-month baseline period before the first G360 test (index) was used to obtain clinical data. Prevalence of AR LBDm was calculated for the presence of 12 mutations (L702H, T878A, H875Y, F877L, W742C, T878S, D891H, W742L, V716M, D891Y, S889G, and V716L) in the AR LBD region and 95% confidence intervals (CIs) were estimated based on Poisson distribution. Association between AR LBDm and real-world overall survival (rwOS) was assessed using log rank tests and Cox proportional hazards models adjusted for age, race/ethnicity, year of test, comorbidity indices, metastasis status, and PC clinical state. Patients with repeated G360 testing were evaluated for AR LBDm status over time. Results: In 16,757 PC patients with a valid ctDNA test result, overall prevalence of AR LBDm was 14.8% (95% CI: 14.2-15.4%). The prevalence of AR LBDm was higher in patients with metastatic castration-resistant PC, older than 75 years, with higher comorbidity index, and received multiple lines of PC treatment. PC patients with AR LBDm had shorter median rwOS (16.2 months) after index compared to patients without those 12 AR LBDm (27.4 months) and patients with undetectable ctDNA (53.1 months) (Table). In 2,030 (12%) of patients with >=2 ctDNA tests (median interval=7.5 months), AR LBDm emerged in 11% of patients and was lost in 4% of patients. Conclusions: This large real-world study shows that AR LBDm varied by patient clinical and treatment characteristics and occurred in early PC states. Consistent with previous research, AR LBDm was associated with worse OS in PC patients. As AR LBDm status can change over time, continuous monitoring of AR LBDm, especially for patients with poor treatment responses, may improve patient outcomes. rwOS by AR LBDm status. AR LBDm Status N No. of Events Median rwOS in Months (95% CI) P-value Undetectable ctDNA 2,211 429 53.1 (48.6, 65.9) <0.0001 Without any of the 12 AR LBDm 12,064 3,704 27.4 (26.5, 28.4) With any of the 12 AR LBDm 2,482 1,050 16.2 (15.1, 17.2)
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs). METHODS Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m 2 , cisplatin 25 mg/m 2 , and nab-paclitaxel 100 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m 2 and cisplatin 25 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle). RESULTS Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC. There was no significant difference in overall survival (OS) between GAP versus GC. Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41. Median progression-free survival (PFS) was similar between groups with median PFS for GAP being 7.5 months (95% CI, 6.4 to 8.5) versus 6.3 months for GC (95% CI, 4.4 to 8.2); HR, 0.89 (95% CI, 0.71 to 1.12); P = .32. In exploratory subset analyses, the OS and PFS benefits of GAP versus GC treatment were greater in locally advanced disease compared with metastatic disease, although not statistically significant (interaction P = .14 for OS and P = .17 for PFS). Moreover, GAP versus GC showed greater improvement in PFS among participants with GBC than those with ICC or ECC (interaction P = .01), but not OS (interaction P = .28). CONCLUSION The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC. More toxicity was encountered with GAP versus GC.
Association between clonal hematopoiesis and survival after nephrectomy in patients with renal cell carcinoma.
589 Background: Clonal hematopoiesis of indeterminate potential (CH) is an age-related phenomenon marked by the clonal expansion of hematopoietic stem cells harboring somatic mutations in the absence of hematologic transformation. These mutations have been linked to worse all-cause mortality from both oncologic and cardiovascular-related risk. Recent pan-cancer studies have also found that CH is common in patients treated for solid tumors and may be associated with survival. We thus sought to characterize CH mutations and their associated clinical impact in patients with localized renal cell carcinoma (RCC) at our institution. Methods: Utilizing a single institutional database of patients who underwent targeted, next-generation sequencing of paired tumor and blood samples (MSK-IMPACT), we identified 311 patients who were diagnosed with localized RCC and underwent nephrectomy. CH mutations were called using a two-tiered filtering schema, requiring a variant allele fraction (VAF) in blood greater than twice that of tumor. Chi-square and Wilcoxon rank-sum tests were used to compare clinical characteristics by CH status. Cox-proportional hazards modeling was used to test the association between CH and survival time following nephrectomy, adjusting for age and presence of diabetes, coronary artery disease (CAD), chronic kidney disease, hypertension, and smoking. We performed separate analyses for patients older and younger than the median age of 56.8 years as these groups had distinct CH, survival, and comorbidity profiles. Results: We assessed variants in 341 genes within the MSK-IMPACT CH database for 311 patients (CH: 79 [25.4%], no CH: 232 [74.6%]) who had localized RCC and underwent a nephrectomy (partial: 114 [36.7%], radical: 197 [63.3%]). DNMT3A (26), PPM1D (7), and TET2 (4) were the most common CH mutations. Patients with CH were older (median age of 64.1 years [IQR: 54.6 to 72.3] vs. 54.8 years [46.1 to 63.5]; p < 0.001) and had higher incidence of CAD (8/48 [16.7%] vs. 12/263 [4.7%], p = 0.004). There was no difference in rates of diabetes, hypertension, or CKD. For patients older than the median age of 57 years, those with CH had a shorter median survival of 86 months [72 to 119] compared to 125 months [96 to NR] (p = 0.02). For patients younger than the median age, age and hypertension were significantly associated with survival time but not CH (p = 0.29). Conclusions: Our study reveals that CH is common in localized RCC patients and may be associated with worse survival especially in older patients. Given the possibility of confounding from other comorbidities, future efforts will focus on identifying the true attributable effect of CH on survival. However, CH clones have been shown to interact with tumor cells and may influence immune surveillance, potentially providing a molecular basis for these findings.
Construction of oriented Zn (002) facets via 3D conductive frameworks for enhanced performance in fiber-based zinc-ion batteries
Zinc-ion batteries (ZIBs) are poised to play a pivotal role in the future energy storage market. However, the undesired growth of zinc dendrites and the prevalence of side reactions pose significant challenges that limit the practical application of ZIBs. The sophisticated structural design and crystal orientation of the Zn anode can effectively suppress the occurrence of zinc dendrites and side reactions. Herein, a highly oriented Zn (002) lattice plane on 3D conductive frameworks [Zn/TiN nanotubes (NTs)] is designed to address uncontrolled dendrite growth, water-induced side reactions, and suboptimal Zn metal utilization in ZIBs. By leveraging an abundance of active sites for Zn2+ adsorption, minimal charge transfer resistance, and the controlled growth of Zn crystal facets, the reversibility and stability of ZIBs can be significantly enhanced during the Zn plating/stripping process. Remarkably, fiber-ZIBs based on Zn/TiN NTs exhibit a large specific capacity, long-term cycling durability, and excellent mechanical properties. This work proposes an approach to achieve highly reversible zinc anodes from the perspective of nanostructure and crystal orientation.
Talent identification of 12-year old male Australian rules footballers: Physical advantages and prognosis for junior and senior national-level selection
Talent identification focuses on the ability to identify and select young athletes who show potential for future sporting success. The aim of this study was to compare the anthropometry and physical performance of male youth Australian Football players selected and not selected into a high performance sports academy program. Its secondary aim was to determine whether selection into a talent development environment at 12 years old affects the odds of selection into subsequent junior national level representative and senior professional Australian Football programs. 168 youth males (11.7 ± 0.4 years) who nominated for the selection process to attend a specialised high school sports academy completed a series of physical and anthropometric assessments. The data collection period occurred over seven years (2013–2019), with a prognostic period between one to ten years. Results found selected 12 years olds were taller and had greater lower body power, speed and aerobic fitness than non-selected athletes. A combination of height, aerobic fitness, and lower body power best distinguished between selected and non-selected players. This discriminant analysis had high accuracy and greater sensitivity than specificity. Further, athletes selected into the talent development environment had a much greater likelihood of being selected into junior state/national (54-fold) and senior professional (5-fold) teams than non-selected athletes. Overall, the findings demonstrate some support for the prognostic ability of selection into a talent development program at 12 years old to predict later selection in the talent pathway. These findings support the role of talent development programs in the development of male Australian footballers.
Monkeypox awareness and public health challenges in conflict affected syria 2024
Impact of prior primary care utilization on limiting racial disparities for prostate cancer diagnosis and mortality.
26 Background: Black men are more likely to develop lethal prostate cancer (PCa) than non-Hispanic White men. It is not clear if this disparity is related to inherent biological causes or differences in social determinants of health including health care access and utilization. We evaluated the impact of prior primary care provider (PCP) utilization on PCa outcomes and its potential for addressing existing racial disparities. Methods: Our retrospective cohort study utilized the SEER-Medicare database and included patients diagnosed with PCa from 2010-2017. PCP visits were binned into absent (0 visits), partial (1-2 visits), and annual (3 visits). Separate multivariable logistic regression models assessed the impact of prior PCP utilization on prostate-specific antigen (PSA) > 20, Gleason score ≥ 8, and metastatic disease at diagnosis. A multivariable competing risk cox proportional hazards model evaluated the association between prediagnostic PCP visits and cause-specific mortality (CSM). Results: Among 41,063 patients, we found the following PCP utilization rates: 3,509 (8.5%) were absent, 20,618 (50.2%) were partial, and 16,936 (41.2%) were annual. Compared with absent PCP utilization, partial utilization was associated with significantly decreased odds of PSA > 20 (Odds Ratio [OR]: 0.36, 95% confidence interval [CI]: 0.33-0.40, p<0.005), Gleason score ≥ 8 (OR: 0.50, 95% CI: 0.46-0.54, p<0.005), and metastatic disease at diagnosis (OR: 0.29, 95% CI 0.26-0.33, p<0.005). Annual PCP utilization had similar directionality and effect sizes on PSA > 20 (OR: 0.35, 95% CI 0.32-0.38, p<0.005), Gleason score ≥ 8 (OR: 0.54, 95% CI 0.50-0.59, p<0.005), and metastatic disease at diagnosis (OR: 0.32, 95% CI 0.29-0.36, p<0.005). Patients with partial and annual PCP utilization had significantly lower risk of CSM when compared with patients with absent utilization (subdistribution hazard ratio (SHR) partial : 0.40, 95% CI 0.37 -0.44, p<0.005 and SHR annual : 0.43, 95% CI 0.39-0.47, p<0.005). Compared to non-Hispanic White patients, Black patients had significantly higher odds of metastatic disease at diagnosis (OR 1.25, 95% CI 1.12-1.07, p<0.005) and CSM (SHR 1.17, 95% CI 1.06-1.28, p<0.005). Adjusting for prediagnostic PCP utilization, there is no significant difference between metastatic disease at diagnosis (OR 1.10, 95% CI 0.98-1.24, p=0.11) or CSM (HR 1.08, 95% CI 0.98-1.18, p=0.13) between non-Hispanic White and Black patients. Conclusions: For patients diagnosed with PCa, higher prediagnostic PCP utilization is associated with earlier stage at diagnosis and lower risk of death from PCa. Disparities seen in metastatic disease and CSM between Black and white men were eliminated when adjusting for prediagnostic PCP utilization suggesting that increasing primary care utilization may help mitigate observed racial disparities between Black and non-Hispanic White men diagnosed with PCa.
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).
552 Background: Substudy 03B of the phase 1/2 KEYMAKER-U03 trial (NCT04626518) was designed to evaluate combination treatments with pembro and investigational agents for previously treated ccRCC. We present results from arms containing only immunotherapy regimens: arm B1 (quavonlimab [qmab; anti–CTLA-4] coformulated with pembro), arm B2 (favezelimab [fave; anti–LAG-3] coformulated with pembro), and arm B3 (pembro + MK-4830 [anti-ILT4]), and the reference (ref) arm (pembro + lenvatinib). Methods: Adults with histologically confirmed ccRCC and disease progression on or after PD-(L)1 inhibitor and VEGF-TKI treatment were enrolled. Patients (pts) in arm B1 could not have received prior anti–CTLA-4 inhibitors. Pts were randomly assigned 1:1 to arms open for enrolment. Treatments were qmab/pembro 25 mg/400 mg IV Q6W in arm B1, fave/pembro 800 mg/200 mg IV Q3W in arm B2, pembro 200 mg IV Q3W + MK-4830 800 mg IV Q3W in arm B3, and pembro 400 mg IV Q6W + lenvatinib 20 mg PO QD in ref arm. Primary end points were safety and confirmed ORR per RECIST v1.1 by blinded independent central review (BICR). Secondary end points included CBR (CR + PR + SD ≥6 months), DOR, and PFS per RECIST v1.1 by BICR, and OS. End points were evaluated in each arm separately; no formal comparisons were made across arms. Efficacy was evaluated in all enrolled pts and safety was evaluated in all pts who received ≥1 dose of treatment. Enrollment was planned for 50 pts in each arm, although enrollment would be stopped if the 6-mo PFS rate was ≤40%. Results: Overall, 20 pts were assigned to arm B1, 20 to arm B2, 24 to arm B3, and 73 to ref arm. Median follow-up was approximately 2 years across arms (B1, 20.6 mo; B2, 23.3 mo; B3, 30.0 mo; ref, 19.4 mo). Efficacy is reported in the table. Grade 3 or 4 treatment-related AEs (TRAEs) were reported in 5/20 pts (25%) in arm B1, 2/19 pts (11%) in arm B2, 2/23 pts (9%) in arm B3, and 36/73 pts (49%) in the ref arm. No grade 5 TRAEs occurred. Conclusions: Preliminary data from qmab/pembro (arm B1) and pembro + lenvatinib (ref arm) showed antitumor activity in pts with ccRCC that progressed on anti–PD-(L)1 and VEGF-TKI therapy. Fave/pembro (arm B2) and pembro + MK-4830 (arm B3) arms did not show clinical activity in this setting. The safety profile of each arm was manageable. Additional arms containing targeted therapies will be reported separately. Clinical trial information: NCT04626518 . Arm B1Qmab/pembron = 20 Arm B2Fave/pembron = 20 Arm B3Pembro + MK-4830n = 24 Ref Pembro + lenvatinibn = 73 ORR (95% CI), % 30 (12-54) 0 (0-17) 0 (0-14) 40 (29-52) CR, n (%) 0 0 0 0 PR, n (%) 6 (30) 0 0 29 (40) CBR (95% CI), % 35 (15-59) 5 (0-25) 0 (0-14) 58 (45-69) DOR, median (range), mo Not reached(5.6+-19.4+) — — 8.3 (2.6+-25.6+) PFS, median (95% CI), mo 5.5(1.5-not reached) 1.6 (1.4-2.8) 1.5 (1.3-1.6) 9.4 (6.9-11.2) 6-mo PFS rate, % 45 20 4 67 OS, median (95% CI), mo Not reached(7.8-not reached) Not reached(9.4-not reached) 11 (7-18) Not reached(21.8-not reached) 12-mo OS rate, % 75 61 44 82
Checkpoint blockade as neoadjuvant strategy: A single-arm meta-analysis of dual PD-1/PD-L1 and CTLA-4 inhibition in urothelial cancer.
783 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the standard treatment for muscle-invasive urothelial cancer (MIUC). In patients who are ineligible or deny chemotherapy, upfront surgery is typically preferred. Immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, have emerged as potential neoadjuvant alternatives for these patients. This single-arm meta-analysis evaluates the efficacy and safety of combining anti-PD-1/PD-L1 with anti-CTLA-4 in MIUC. Methods: A systematic review of PubMed, Cochrane, ClinicalTrials.gov, and EMBASE identified clinical trials assessing neoadjuvant anti-PD-1/PD-L1 plus anti-CTLA-4 therapy in resectable, non-metastatic high-risk or muscle-invasive urothelial cancer. Outcomes included pathological complete response (pCR), pathological downstaging (<ypT2N0), recurrence-free survival (RFS), mortality, progressive disease (PD), and treatment-related adverse events (TRAEs). Pooled proportions and 95% confidence intervals (CI) were calculated using a random-effects model. Heterogeneity was assessed using I² statistics. Results: 137 patients were included from 4 clinical trials, encompassing 6 cohorts. Two cohorts received Durvalumab plus Tremelimumab (D+T), and four cohorts received Nivolumab plus Ipilimumab (N+I). Of these, 73.7% were cisplatin-ineligible, and 15.3% had upper tract urothelial carcinoma (UTUC). The overall pooled pCR rate was 35% (CI: 27–44%, I² = 11%), with no significant subgroup difference between in muscle-invasive bladder cancer (MIBC)-only studies compared to studies that included patients with UTUC (p-interaction = 0.33). The downstaging rate was 47% (CI: 36–58%, I² = 41%). One-year RFS was 81% (CI: 64–92%, I² = 44%), while PD occurred in 19% of patients (CI: 9–36%, I² = 44%). The mortality rate was 16% (CI: 10–26%, I² = 11%). Grade ≥3 TRAEs were reported in 29% of patients (CI: 18–44%, I² = 61%). Additionally, TRAEs grade ≥ 3 were numerically less common in the D+T group (22%, 95% CI: 12–35%, I² = 0%) compared to the N+I group (33%, 95% CI: 16–56%, I² = 68%), although this difference was not statistically significant (p-interaction = 0.33). Conclusions: Neoadjuvant anti-PD-1/PD-L1 combined with anti-CTLA-4 therapy demonstrates promising pCR, pathological downstaging rates and 1-year RFS in patients with MIUC. Despite Grade ≥3 TRAEs occurring in nearly one-third of patients, the majority were manageable. While these results highlight the potential of this combination for patients who are ineligible or deny NAC, randomized controlled trials are needed to refine patient selection and validate these findings.
Patient perceptions about their treatment for muscle-invasive bladder cancer (MIBC) over the last decade.
765 Background: The Bladder Cancer Advocacy Network (BCAN) is a national patient advocacy organization that has promoted awareness about the signs, symptoms, diagnosis, treatment and need for a multidisciplinary approach to the care of patients with MIBC. To better understand the impact of these efforts, and patients’ perceptions of their care, we surveyed bladder cancer patients initially in 2013 and again in 2023 through the BCAN website. Methods: We developed a 32-question survey with input from physicians, nurses, patients and caregivers. The survey was posted on the BCAN website 06/13-10/14 (Cohort A) and again from 06/23-04/24 (Cohort B). Questions focused on time from initial symptoms to diagnosis and treatment; proportion seeing a medical oncologist (MO) or radiation oncologist (RO); and treatments offered/received. Results: Overall, 337 (243 and 94) patients completed the survey. Respondents were self-selected and most were from the US/Canada, male, white, and had at least an undergraduate education. Median age was 61 (cohort A; range 31-93) and 63 (cohort B; range 38-87), respectively, at the time of diagnosis. The most common presenting symptom was hematuria (88% vs 78%, p=0.05). Overall, 35% vs 30% (p=0.56) waited > 3 months to seek medical attention; in 38% and 43% it took > 3 months to obtain a pathologic diagnosis (p=0.76). Men were more likely than women to be diagnosed within 1-2 months of seeking medical attention: Cohort A (68% vs 47% p=0.03) and Cohort B (70% vs 37%, p=0.03). In both cohorts, prior to surgery, approximately 50% saw a medical oncologist and were offered neoadjuvant chemotherapy; however, less than 10% saw a radiation oncologist and were offered bladder sparing approaches. Most patients reported having all the necessary information, knowing the right questions to ask, and were satisfied with their choices. A higher proportion in Cohort A vs Cohort B felt they had enough time to make their decisions (77% vs 67%, p=0.004). Conclusions: Despite nearly two decades of advocacy, there are ongoing areas of unmet need in MIBC. These include reducing time to definitive diagnosis and treatment, especially in women, and increasing multidisciplinary assessments prior to definitive surgery. Respondents were self-selected, had access to the BCAN website, and were highly educated, potentially limiting the generalizability of these results.
ZnO/Cu2S PN-junctions with built-in electric field for enhanced CO2 electroreduction
A full stack strategy, including facilitating the capture of CO2 molecules on catalysts, regulating intermediates, and releasing products, is highly needed to break the bottleneck for CO2 electroreduction to CO. The electric field is expected to promote capture of CO2, reduce energy barriers of reaction, and efficiently release CO, boosting the overall CO2 reduction reaction (CO2RR) activities. In this work, ZnO/Cu2S PN-junctions with a built-in electric field were fabricated. Kelvin probe force microscopy measurements confirmed that the presence of the built-in electric field facilitates the adsorption of more CO2 molecules onto the catalyst surface. Furthermore, theoretical calculations and electrochemical testing demonstrated that the built-in electric field lowers the reaction energy barrier and effectively modulates the reaction intermediates, contributing to enhanced catalytic performance. This work provides a full stack strategy to improve CO2RR performance and thinking for gas-fed catalytic reactions.
Cross-cultural adaptation and multicentric validation of the Italian version of the Simplified Evaluation of CONsciousness Disorders (SECONDs)
Introduction The Coma Recovery Scale-Revised (CRS-R) is the recommended tool to assess consciousness in patients with prolonged Disorders of Consciousness (pDoC). However, the time needed to administer it may limit its use. A shorter tool has been validated: the Simplified Evaluation of CONsciousness Disorders (SECONDs). This multicentre study aimed to develop and validate a cross-cultural adaptation of the SECONDs into Italian. Methods An interdisciplinary expert team, from both Fondazione Don Carlo Gnocchi and Istituto Neurologico Carlo Besta, led the translation processes. Independent certified translators were also involved in a blinded modality. Patients diagnosed with Unresponsive Wakefulness Syndrome (UWS) or Minimally Conscious State (MCS) admitted to 3 Italian rehabilitation units were enrolled. The CRS-R and SECONDs were administered in 5 sessions over two weeks by 3 blinded examiners at each center (3 times, with 2 sessions conducted by the same examiner). Weighted Fleiss’ kappa and Spearman correlation coefficients were used to assess intrarater and interrater reliability and concurrent validity. Results Sixty adults with pDoC were assessed: 23 women; median age: 64 years; 14 trauma, median post-onset time: 2 months. Intrarater and interrater reliability showed almost perfect agreement (kappa coefficients 0.968 and 0.935, respectively; p<0.001). The comparison of CRS-R vs. SECONDs on the same day or the best out of 5 SECONDs/CRS-R led to a substantial to almost perfect agreement both for the total score of the CRS-R and the SECONDs’ Additional Index (ρ = 0.772–1.000; p<0.001) and for the consciousness diagnosis (k = 0.784–0.935; p<0.001). The disagreement rate between the overall best diagnosis of the SECONDs and the best CRS-R diagnosis was 6.7%. Conclusion The Italian version of the SECONDs has been cross-culturally adapted to serve as a shorter assessment tool for the diagnosis of pDoC. Our study shows its excellent reliability and concurrent validity when compared to the CRS-R.
Circuit implementation and analysis of a quantum-walk based search complement algorithm
Association between molecular changes and perioperative immunotherapy in patients with advanced clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
573 Background: Immunotherapy (IO) combinations are standard first-line treatments for advanced clear cell renal cell carcinoma (ccRCC). However, identifying patients who will respond to IO remains a challenge, complicating treatment selection. Previous studies on biomarkers for IO response or resistance often used unmatched biopsies, limiting insights into therapy-induced changes due to patient heterogeneity. This study aims to evaluate transcriptomic changes in matched pre- and post-IO patient samples to detect treatment-induced gene and pathway alterations. Methods: A retrospective analysis was performed on patients with advanced ccRCC receiving IO-based therapies who underwent cytoreductive nephrectomy (Nx) at UT Southwestern/Simmons Comprehensive Cancer Center (SCCC). Patient-level data were extracted from an IRB-approved registry, and samples were collected from the SCCC biorepository. The primary endpoint was to identify IO-induced transcriptomic changes using paired pre- and post-treatment tissue sections. Regions of interest (ROIs) were selected based on pan-cytokeratin (PanCK) expression using the GeoMx Digital Spatial Profiler (DSP, NanoString). Whole-transcriptome analysis was performed, and data were analyzed using a two-sample t-test. Results: We identified 58 patients with advanced ccRCC who received perioperative IO regimens and deferred Nx. Of these, 7 patients had paired pre- and post-treatment samples sequenced (3 received ipilimumab/nivolumab, 3 nivolumab, and 1 pembrolizumab/axitinib). Individual analysis of each matched pair revealed an average of 92 DE genes (log fold-change >1.3, p<0.01). Gene set enrichment analysis (GSEA) showed differential enrichment in pathways such as immune response (interleukin signaling, JAK/STAT signaling, innate immune system activation), translational machinery, MHC-mediated tumor antigen presentation, axon guidance, and cell death pathways. Notably, a key post-IO downregulated pathway was GPCR signaling, which is implicated in tumor growth and metastasis. Taken in aggregate, bulk analysis revealed only 9 differentially expressed (DE) genes in PanCK+ tumor regions, and GSEA did not identify commonly enriched pathways. Conclusions: While bulk analysis detected few changes, individual pair analysis highlighted significant transcriptomic shifts in RCC tumors post-IO. These RCC tumors upregulated gene expression in several immune pathways, including interleukin, JAK/STAT, and innate immune pathways. This study underscores the importance of matched samples to capture patient-specific changes after IO combinations.
Outcomes for <sup>177</sup> Lu-PSMA-617 with and without concurrent use of ARPIs in patients with mCRPC.
112 Background: We now have more than a decade of experience using Androgen Receptor Pathway Inhibitors (ARPIs) across various disease states of prostate cancer, and the safety of their combination with Lutetium-177–PSMA-617 has been demonstrated in VISION and other large randomized clinical trials. However, real-world data on treatment patterns and outcomes involving combination therapies with 177 Lu-PSMA-617 remain limited. Methods: For this analysis, we utilized the Mayo Clinic Rochester radiopharmaceutical database, a prospectively maintained retrospective database containing all patients who received 177 Lu-PSMA-617 at our institution. We focused on patients who started treatment from March 2022 to March 2023. Patients receiving an ARPI (abiraterone acetate, enzalutamide, apalutamide, or darolutamide) during the course of 177 Lu-PSMA-617 treatment were identified, inclusive of patients who continued using an ARPI prescribed as a prior line of treatment and those who started (i.e., switched) to a new ARPI. Baseline clinicopathologic and imaging characteristics were abstracted and compared using the Mann-Whitney U and Chi-square tests. Best PSA response during treatment was reported as a percent decline from baseline. Survival was calculated from the date of the first cycle of 177 Lu-PSMA-617. PSA50 response and overall survival (OS) outcomes for the two groups (concurrent use of ARPI vs. 177 Lu-PSMA-617 alone) were compared using the Chi-square test and Kaplan-Meier method, respectively. A multivariate Cox regression analysis was performed, including established prognostic factors. Results: An ARPI was prescribed to 106 of the 256 patients (41.4%) starting 177 Lu-PSMA-617 in the interval of March 2022 to March 2023. With regards to baseline characteristics, those receiving an ARPI concurrently with 177 Lu-PSMA-617 had a lower PSA (3.4 vs 29.7 ng/mL, p < 0.001) and a lower frequency of bone (77.4% vs. 87.4%, p = 0.035) and visceral metastases (18.9 vs 34%, p = 0.008) at start of treatment. Median follow-up for the overall cohort (IQR) was 19.1 months (8.7 – 23.6). Patients receiving an ARPI plus 177 Lu-PSMA-617, as compared to 177 Lu-PSMA-617 alone, were more likely to complete all 6 planned doses of treatment (63.2% vs. 48.7%, p < 0.001), though the PSA50 response rate was similar (49.1% vs 47.3%, p = 0.786). Median OS [95% CI] for the overall cohort was 21.3 [16.7 – 25.9] months and significantly longer for those receiving ARPI with 177 Lu-PSMA-617 (NR [NE – NE]) as compared to 177 Lu-PSMA-617 alone (15.3 mo [11.6 – 19.1], p < 0.001). However, on multivariate analysis including known prognostic variables, use of ARPI was not independently associated with improved survival (HR = 1.03 [CI: 0.68 to 1.55], p = 0.891). Conclusions: Patients receiving an ARPI with 177 Lu-PSMA-617 were more likely to complete all 6 cycles of treatment, but no clear differences in survival were observed on multivariate analysis.
Use and clinical outcomes of androgen receptor inhibitors (ARIs) for non-metastatic castration resistant prostate cancer (nmCRPC) at labeled doses in Japan.
170 Background: The androgen receptor inhibitors (ARIs) darolutamide (DAR), enzalutamide (ENZ), and apalutamide (APA) are recommended for treatment of nmCRPC in Japan. However, not all patients (pts) start ARI treatment at the label dose. This study provides real-world variations in nmCRPC treatment dosing in Japan and their impact on pt outcomes. Methods: Retrospective observational cohort study using administrative health claims data from >480 acute care hospitals in Japan’s Medical Data Vision (MDV) database. Pts who started an ARI for the first time from 2/2020–4/2023 were classified into 3 cohorts based on the ARI (DAR, ENZ, or APA) prescribed for nmCRPC. This study describes the starting dose, treatment discontinuation and duration, and time to progression to metastatic castration-resistant prostate cancer (mCRPC) among pts who initiated treatment with ARIs at the label dose or lower (<100% label dose). Results: A total of 2746 pts with nmCRPC were treated with ARIs (DAR n=418; ENZ n=1898; APA n=430). Of these, the proportion of pts initiating treatment at the label dose was DAR 78%, ENZ 58%, and APA 62%. Of the pts who continued treatment at 6 months, the proportions receiving the label dose were DAR 76%, ENZ 57%, and APA 45%. Pts who initiated an ARI at the label dose tended to be younger and treated at cancer-specialist hospitals (Table). Among pts who initiated an ARI at the label dose, the DAR cohort had numerically lower discontinuation rates (49% vs ENZ [63%] and APA [74%]), and the probability of progression was lower for the DAR cohort vs ENZ and APA (Table). Among pts who initiated an ARI at a low dose, all 3 cohorts had similar discontinuation and progression rates. Conclusions: A higher proportion of Japanese pts receiving DAR were treated at the label dose during the study period and were more likely to stay on treatment. Within each dose subgroup, pts receiving DAR progressed more slowly to mCRPC than those receiving ENZ or APA. Clinical trial information: N/A. Label dose Low dose (<100% label dose) DAR (n=324) ENZ (n=1097) APA (n=266) DAR (n=94) ENZ (n=796) APA (n=164) Age, median (Q1, Q3), years 80 (75–85) 79 (73–84) 78 (72–83) 84 (78–88) 84 (79–88) 79 (74–84) Charlson Comorbidity Index score ≥1, n (%) 124 (38) 471 (43) 111 (42) 33 (35) 397 (50) 95 (58) Designated cancer hospitals, n (%) 262 (81) 789 (72) 206 (77) 76 (81) 529 (67) 116 (71) Follow-up, arithmetic median (Q1, Q3), months 19 (11–25) 21 (13–31) 27 (17–34) 17 (10–26) 21 (12–31) 21 (12–30) Median (95% CI) time to discontinuation, months 17.6 (13.3−24.8) 11.6 (10.4−13.4) 5.0 (3.9−7.1) 12.8 (7.2−20.2) 12.9 (11.8−14.3) 10.8 (7.6−14.0) KM probability of mCRPC progression at 12 months (95% CI)* 0.16 (0.12−0.21) 0.27 (0.24−0.29) 0.29 (0.24−0.35) 0.18 (0.11−0.28) 0.22 (0.19−0.25) 0.24 (0.18−0.32) *Median time to mCRPC progression was not reached during the study period.